Pernicious Anemia

Detailed Overview

It is the most common cause of severe vitamin B12 deficiency globally. The disease is mediated by autoantibodies against parietal cells and intrinsic factor itself. Because the liver stores significant amounts of B12 (enough for 3-5 years), clinical symptoms take years to develop. Once depleted, impaired DNA synthesis affects all rapidly dividing cells, leading to macrocytic erythrocytes and hypersegmented neutrophils. Neurologically, B12 deficiency impairs the methylation of myelin, leading to subacute combined degeneration of the spinal cord (demyelination of dorsal and lateral columns).

Epidemiology & Demographics

Prevalence is approximately 0.1% in the general population, but rises to 1.9% in individuals over age 60. Highest prevalence in individuals of Northern European and African descent. Women are affected slightly more than men.

Etiological Mechanism

It is a chronic, CD4 T-cell mediated autoimmune disease targeting the H+/K+-ATPase proton pump of gastric parietal cells. It is frequently associated with other autoimmune endocrinopathies (Type 1 diabetes, autoimmune thyroid disease, vitiligo, Addison's disease).

Primary Causes

The primary cause is the autoimmune destruction of the gastric body and fundus mucosa (autoimmune metaplastic atrophic gastritis, AMAG), leading to achlorhydria and absent intrinsic factor.

• Other Autoimmune Diseases: Personal or family history of Hashimoto's thyroiditis, Graves' disease, or Type 1 diabetes.
• Age: Risk increases with age; peak incidence is at 60-70 years.
• H. pylori infection: Chronic H. pylori infection may trigger gastric autoimmunity via molecular mimicry in some patients.

Autoimmune destruction leads to autoimmune atrophic gastritis. The loss of parietal cells results in achlorhydria (low stomach acid), which impairs the release of B12 from food proteins. Crucially, the lack of intrinsic factor prevents B12 from being transported across the enterocytes in the terminal ileum. B12 is a crucial cofactor for two enzymes: methionine synthase (needed for DNA synthesis, lack thereof causes megaloblastic anemia) and methylmalonyl-CoA mutase (needed for myelin synthesis, lack thereof causes neurological deficits).

Characteristic Clinical Presentation

• Fatigue & Weakness: Severe lethargy and low exercise tolerance secondary to anemia.
• Glossitis: Sore, smooth, beefy-red tongue (Hunter's glossitis).
• Neurologic Symptoms: Symmetrical paresthesias (tingling/numbness) in the hands and feet, loss of vibratory and position sense.
• Neuropsychiatric Changes: Memory loss, irritability, depression, and in severe cases, 'megaloblastic madness' or dementia.

Physical Examination Signs

• Lemon-yellow skin tint (combination of pallor from anemia and mild jaundice from ineffective erythropoiesis)
• Ataxic gait and positive Romberg sign
• Decreased deep tendon reflexes initially, progressing to spasticity and hyperreflexia (upper motor neuron signs)

• Subacute Combined Degeneration: Irreversible damage to the dorsal columns and lateral corticospinal tracts if left untreated.
• Gastric Cancer: 2-3x increased risk of gastric adenocarcinoma and gastric neuroendocrine (carcinoid) tumors due to hypergastrinemia.
• Severe Anemia/Heart Failure: High-output heart failure due to profoundly low hemoglobin (<5 g/dL).

Diagnostic Criteria & Guidelines

Diagnosis requires demonstrating B12 deficiency (low serum B12 with elevated methylmalonic acid and homocysteine) in the setting of megaloblastic anemia, accompanied by autoimmune markers (positive Anti-Intrinsic Factor antibodies or Anti-Parietal Cell antibodies).

Differential Diagnosis

• Folate Deficiency Anemia (has identical CBC findings but normal methylmalonic acid and NO neurologic signs)
• Dietary B12 Deficiency (e.g., strict vegans)
• Myelodysplastic Syndrome (MDS)
• Multiple Sclerosis or Peripheral Neuropathy of other etiologies

Laboratory Tests & Biomarkers

• Serum Vitamin B12: Low (typically < 200 pg/mL).
• Methylmalonic Acid (MMA) & Homocysteine: Both markedly elevated (highly sensitive for B12 tissue deficiency).
• Complete Blood Count (CBC): Low Hemoglobin, elevated MCV (>100 fL, often >115 fL). Peripheral smear shows hypersegmented neutrophils (≥6 lobes) and macro-ovalocytes.
• Anti-Intrinsic Factor Antibodies: Positive (highly specific, ~100%, but sensitivity is ~50-70%).

Imaging Modalities & Findings

• Upper Endoscopy (EGD):
• Spinal MRI (in severe cases):

• Stage 1: Pre-clinical
  Autoantibodies present, decreasing B12 levels, but asymptomatic with normal CBC.
• Stage 2: Hematologic
  Development of macrocytic anemia and mild symptoms like fatigue and glossitis.
• Stage 3: Neurologic
  Onset of peripheral neuropathy and subacute combined degeneration of the spinal cord.

Second-Line & Adjunctive Therapy

High-dose oral Cyanocobalamin (1,000 to 2,000 mcg daily). Despite the lack of intrinsic factor, about 1% of a massive oral dose is absorbed via passive diffusion, which is sufficient for maintenance in compliant patients. However, IM injections are preferred for initial therapy and in patients with neurological symptoms.

Surgical & Procedural Management

None for the anemia itself. Endoscopic mucosal resection or gastrectomy may be required if gastric cancer or large carcinoid tumors develop.

Recommended Lifestyle Changes

Patient Counseling & Advice

Inform the patient that this is a lifelong condition requiring permanent B12 replacement. Reassure them that with treatment, the anemia will completely resolve within weeks. Warn them that neurological symptoms may take months to improve and, if long-standing before treatment, may be permanent. Discuss the need for periodic monitoring for gastric cancer.

Follow-Up & Monitoring Schedule

Check CBC and reticulocyte count 7-10 days after starting therapy (reticulocyte crisis indicates successful treatment). Potassium should be monitored during the first week. EGD is recommended at diagnosis to evaluate for gastric neoplasms, with follow-up intervals determined by gastroenterology based on findings.

Preventive Strategies

Cannot be prevented due to autoimmune nature. Secondary prevention (preventing severe complications) is achieved through early recognition and lifelong B12 therapy.

Excellent with lifelong treatment; normal life expectancy. Hematologic abnormalities reverse rapidly. Neurologic recovery is inversely proportional to the duration of symptoms prior to treatment.